Navigation Links
Carrington Settles Lawsuit, Sets Sights On Future
Date:2/1/2008

IRVING, Texas, Feb. 1 /PRNewswire-FirstCall/ -- Carrington Laboratories, Inc. (OTC Bulletin Board: CARN) today announced the settlement of a lawsuit filed in February 2007 by Glamorpuss, Inc. The value of the settlement was not disclosed. Carrington maintains its position and denies any wrongdoing in the matter.

"We are eager to focus our full attention to analyzing our business and advancing DelSite's work with the bird flu vaccine, and needed to resolve some outstanding issues that occupied our time and resources at the corporate level," said Carlton E. Turner, PhD, Carrington's president and CEO. "We are glad to put this lawsuit behind us without significant financial impact."

DelSite Biotechnologies, Inc., is Carrington's wholly owned subsidiary that is developing its propriety GelSite(R) technology designed to provide controlled release of peptide and protein-based drugs and vaccines. DelSite is currently developing a nasal powder vaccine using its GelVac(TM) formula with the H5N1 avian flu antigen and conducting studies which are funded in part by two grants from the NIAID (National Institute of Allergy and Infectious Diseases) of NIH (National Institutes of Health) under the Department of Health and Human Services.

"This is a very exciting time for us," Dr. Turner said. "Last month DelSite announced the successful completion and results of preclinical toxicology studies of the GelVac(TM) nasal powder influenza vaccine under FDA-reviewed protocols. This clears our path to proceed to a Phase I clinical trial in humans later this year. We are, in fact, awaiting arrival of the H5N1 antigen and are fully prepared to manufacture the vaccine for clinical testing upon its arrival. This vaccine system, if successful, could very well revolutionize how vaccines are formulated, stored, distributed and administered."

"GelVac(TM) has been shown to work with many antigens," Dr. Turner continued. "It is stable at room temperature, requires
'/>"/>

SOURCE Carrington Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
2. Carrington Reports Second Quarter 2007 Results
3. Carrington Completes $8 Million Financing
4. Carrington Reports on ISO 9001:2000 Inspection at Sabila Industrial in Costa Rica
5. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
6. Carrington and DaySpring Pharma Extend and Formalize Agreement for Distribution of Diabetic and Radiation Products Into Physician Market
7. Carrington Laboratories Common Stock Now Trading on the OTC Bulletin Board: CARN.OB
8. Carrington Reports on ISO 9001:2000 Inspection
9. Carrington Reports Third Quarter 2007 Results
10. Carrington Retains Milkie/Ferguson to Explore Financial Alternatives
11. Discover Testing Settles the Drinking Water Debate: Tap vs. Bottled
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Research and Markets  has announced the addition of the ... report to their offering. This report ... in US$ Thousands. The report provides separate comprehensive analytics for ... , Asia-Pacific , and Rest of ... 2012 through 2020. Market data and analytics are derived from ...
(Date:8/19/2014)... In November 2012, the European Union (EU) ... (PBRER) in a new PSUR – responding to the increasing ... of a drug. Adopted in many regions, the main objectives ... a comprehensive and critical analysis of new or emerging information ... any new evidence of the potential benefits of a drug; ...
(Date:8/18/2014)... 2014) -- A new therapy developed by researchers ... College of Medicine and Columbia University Medical Center ... interventional cardiovascular disease treatment. , The researchers ... molecular therapy could selectively inhibit blood vessel re-narrowing ... procedure using a balloon catheter to open narrowed ...
(Date:8/18/2014)... HIV Infection Drug Market and Pipeline Insight is a ... infection and the number of deaths due to AIDS has ... the globe. It has been estimated that the death rate ... with the rates for children being even much lower. A ... has been the improved access to antiretroviral drugs and therapy ...
Breaking Biology Technology:Global Solid Oxide Fuel Cells (SOFCs) - Strategic Business Report 2014 2Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks 2Selective therapy may improve artery repair after interventional cardiovascular procedures 2Selective therapy may improve artery repair after interventional cardiovascular procedures 3Global HIV Infection Drug Market Overview 2Global HIV Infection Drug Market Overview 3Global HIV Infection Drug Market Overview 4
... Feb. 4 Art,s Way Manufacturing, Inc. (Nasdaq: ... subsidiary, Art,s Way Scientific, Inc. - Buildings For ... - http://www.buildingsforscience.com/ The new site, reflective ... enhanced, clean and more user-friendly.Art,s Way Scientific ( ...
... (Nasdaq: KNDL ) announced today that it will ... closes on Tuesday, Feb. 24, 2009. The Company will host ... 25 at 8:30 a.m. Eastern Time. A question and answer ... participate in the telephone conference call, interested parties in the ...
... Patients Achieved an Objective Tumor Response by End of ... Inc. (Nasdaq: PPHM ) today reported that ... endpoint in the first stage of its ongoing Phase ... cancer (NSCLC). The open-label, Simon two-stage study is ...
Cached Biology Technology:Art's Way Manufacturing Announces Launch of New Web Site For Art's Way Scientific - Buildings For Science 2Art's Way Manufacturing Announces Launch of New Web Site For Art's Way Scientific - Buildings For Science 3Kendle Announces Details Regarding Fourth Quarter and Full-Year 2008 Earnings and 2009 Guidance Release, Webcast and Conference Call 2Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study 2Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study 3Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study 4
(Date:8/19/2014)... DIEGO, Calif. (August 19, 2014) Daylight was breaking ... MY Hanse Explorer. Between sips, about a dozen scientists ... and slip below the surface to collect water samples ... would tinker with the whirring gizmos and delicate machinery ... single goal: Be the first research group to bring ...
(Date:8/18/2014)... person,s gut may protect against or increase susceptibility to ... bacterial intestinal inflammation, according research published this week in ... American Society for Microbiology. The study also found that ... one,s gut bacteria composition. , "It has been known ... in the gut, can protect a person from colonization ...
(Date:8/18/2014)... UT Southwestern Medical Center have found a new way that ... known as long non-coding RNA. , The internal body clocks, ... functions, from waking and sleeping to body temperature and hunger. ... influenced by external cues such as light and temperature. , ... many organisms, what they do in the body, and how ...
Breaking Biology News(10 mins):Sequencing at sea 2Sequencing at sea 3What's in your gut? Certain bacteria may influence susceptibility to infection 2Researchers obtain key insights into how the internal body clock is tuned 2Researchers obtain key insights into how the internal body clock is tuned 3
... seeking to detect bioterrorism attacks, doctors diagnosing diseases ... a new ally in a Lawrence Livermore National ... as the Lawrence Livermore Microbial Detection Array (LLMDA), ... to detect within 24 hours any virus or ...
... prestigious Pierre Delmas Prize: An ESCEO-IOF/Servier Achievement Award was ... at the Claude Bernard University of Lyon, France. ... honour of the late Pierre D. Delmas, the world ... (IOF). The grant of 40,000 Euros, courtesy of Servier, ...
... A prescription drug already approved to treat genital warts and ... effectiveness of future vaccines for bacterial and viral diseases, such ... appear in ACS, Molecular Pharmaceutics , a bi-monthly journal. ... Research Center and UC-Berkeley note that vaccines prepared from weakened ...
Cached Biology News:New LLNL detection technology identifies bacteria, viruses, other organisms within 24 hours 2New LLNL detection technology identifies bacteria, viruses, other organisms within 24 hours 3Winner of Pierre Delmas Prize announced at World Congress on Osteoporosis 2010 2
Normal human serum, single donor...
... Quality ISO 9001:2000 Certified ... All Precedures Validated, SOP's Training ... Process for All Procedures GLP Documentation Upon ... one stop shopping point for all your ...
Human IL-17D Affinity Purified Polyclonal Ab...
BBS/Glycerol/Casein Block and Diluent - 10X Concentrate, 1 L...
Biology Products: